Coronavirus third wave 'dangerous' for kids, vaccine trial approved

Bharat Biotech International Ltd (BBIL) had proposed to carry out a Phase II-III clinical trial of Covaxin in the age group of two to 18 years.

As rapid regulatory response, the proposal was deliberated in Subject Expert Committee (SEC) (Covid-19) on May 11 this year. Coronavirus' third wave can be 'dangerous' for kids, so the necessary steps are being taken care of